Thank you for subscribing!
Finfeed Archived Mar 18, 2020
The recent completion of the monitoring phase of Antisense Therapeutics Limited's (ASX: ANP) ATL1102 Phase II Duchenne Muscular Dystrophy (DMD) trial remains on track for the end of March 2020.
Next Investors Archived Mar 02, 2020
Biotech company Regeneus (ASX:RGS) is a regenerative medicine company, and the therapy is a novel stem cell therapy.
Finfeed Archived Feb 28, 2020
Antisense Therapeutics Limited (ASX:ANP) has appointed Gil Price M.D. as Consultant Medical Director. Dr. Price is a clinical physician trained in internal medicine with a long-standing focus in drug development, adverse drug reactions, drug utilization and regulation.
Finfeed Archived Dec 11, 2019
PharmAust Ltd (ASX:PAA), a clinical-stage oncology company that’s developing targeted cancer therapeutics for humans and animals, reports that it has expanded site recruitment for its anti-cancer trial in pet dogs with treatment naïve B cell lymphoma.
Get expert stock analysis direct in your inbox
Finfeed Archived Oct 23, 2019
The TechKnow Invest Roadshow provides retail and institutional investors, as well as brokers, an opportunity to learn more about a range of tech and biotech companies.
Finfeed Archived Oct 21, 2019
Imugene Limited (ASX:IMU) has provided a promising update on the preliminary clinical development plan (CDP) for the proposed exclusive license of the patents covering the CF33 oncolytic virus technology.
Finfeed Archived Oct 01, 2019
Change Financial Limited (ASX:CCA) closed up 332% to finish at 54c on $11.2 million stock traded on the back of the successful completion of the build of its innovative payments and card issuing platform marking a key milestone for the company.
Finfeed Archived Sep 11, 2019
The S&P/ASX 200 Healthcare Sector blitzed the rest of the market, increasing 12.7% against the ASX 200 which interestingly by the start of September was already back in positive territory, up 4.5%.
Finfeed Archived Sep 09, 2019
Imagion Biosystems (ASX:IBX) advised the market of early-stage evidence that the technology could have applications in improving magnetic resonance imaging (MRIs).
Finfeed Archived Sep 04, 2019
Immuron’s (ASX:IMC) share price has surged on the back of extremely promising clinical results.
Finfeed Archived Sep 02, 2019
Travelan is Immuron’s (ASX:IMC) over-the-counter gastrointestinal and digestive health supplement, and global sales increased by 29.5% year-on-year in fiscal 2019 to $2.39 million.
Finfeed Archived Jul 25, 2019
Queenstown, the New Zealand extreme sport mecca, hosts the annual Bioshares Biotech Summit, gathering together some of the best long-standing and emerging biotech companies in the country to talk all things trials, tribulations and potential cures for cancer.
Finfeed Archived Jul 03, 2019
BPH Energy Ltd (ASX:BPH) has provided a promising update relating to further trials for the BARM System of investee Cortical Dynamics Ltd.
Finfeed Archived Jun 12, 2019
Immuron Ltd (ASX:IMC; NASDQ:IMRN), has provided an extremely promising update on the company’s cooperative research and development agreements with the US Department of Defence, no doubt contributing to its strong share price performance on the back of this news.
Next Investors Archived Apr 08, 2019
Genetic Technologies (ASX:GTG) is a provider of world-leading genetic risk assessment test products.
Finfeed Archived Apr 02, 2019
Imugene Limited (ASX:IMU), a leading clinical stage immuno-oncology company, has today released new data on the Phase lb study of its HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 Annual Meeting in Atlanta, Georgia.
Join Our Mailing List
